- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01292824
Pilot Study of Hepatitis C Virus Entry Inhibitor (ITX 5061) in Liver Transplant Recipients (ITX5061)
Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hepatitis C virus (HCV) infection is common and treatment options at present are limited. Recurrence of HCV infection after liver transplantation is inevitable and disease progression is rapid when compared with disease in the non-transplanted liver.
Studies of ITX 5061 in vitro have shown it to be a potent inhibitor of HCV entry into hepatocytes, through blocking the interaction of the virus with scavenger receptor BI suggesting it may reduce graft re-infection rates after liver transplant.
There are no studies of treatments to block host receptors for HCV and the investigators hypothesize that ITX 5061 will modulate HCV kinetics in the early phase post liver transplant.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
West Midlands
-
Birmingham, West Midlands, United Kingdom, B15 2TH
- University Hospital Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old, ≤ 65 years old
- Plasma HCV RNA positive at time of listing for liver transplantation
- Accepted for liver transplantation for any of:
- End-stage liver disease due to HCV infection
- End-stage liver disease due to HCV infection and alcohol related liver disease (ALD)
- HCC due to HCV
Exclusion Criteria:
- Refusal or inability to give informed consent
- Viral co-infection with either hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
- Pregnancy or breastfeeding
- Women, of child-bearing potential, who are not willing to practice effective contraception
- Men, sexually active with women of child-bearing potential, who are not willing to practice effective contraception
- Any situation that in the Investigator's opinion may interfere with optimal study participation
- Participation in any clinical study of an investigational agent within 30 days of recruitment
- Transplantation with a donor organ from a HCV positive individual
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Standard liver transplant care
Liver Transplantation as per Standard of Care
|
|
EXPERIMENTAL: ITX 5061
Liver Transplantation as per Standard of Care + ITX5061
|
ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the safety of ITX 5061 in liver transplant recipients
Time Frame: 90 days
|
Safety will be assessed by determination of the frequency of:
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine whether treatment leads to an alteration in HCV RNA kinetics in the first week after liver transplantation
Time Frame: One week
|
Hepatitis C virus titers will be measured at multiple times in the peri- and immediate post-operative period and kinetics assessed at 7 days after liver transplant.
|
One week
|
To determine whether any change in early viral kinetics is sustained
Time Frame: 90 days
|
Hepatitis C virus titers will be measured at multiple times in the post-operative period and kinetics assessed at 90 days after liver transplant.
|
90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David J Mutimer, FRCP, University of Birmingham
Publications and helpful links
General Publications
- Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, McKeating JA, McKelvy J, Wong-Staal F. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol. 2011 Jan;54(1):48-55. doi: 10.1016/j.jhep.2010.06.024. Epub 2010 Aug 21.
- Rowe IA, Tully DC, Armstrong MJ, Parker R, Guo K, Barton D, Morse GD, Venuto CS, Ogilvie CB, Hedegaard DL, McKelvy JF, Wong-Staal F, Allen TM, Balfe P, McKeating JA, Mutimer DJ. Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl. 2016 Mar;22(3):287-97. doi: 10.1002/lt.24349.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RG_10-104
- 2010-020358-32 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
University Health Network, TorontoCompletedChronic Hepatitis C InfectionCanada
Clinical Trials on ITX 5061
-
National Institute of Allergy and Infectious Diseases...CompletedHepatitis CUnited States, Puerto Rico
-
Schiano, Thomas D., MDiTherX Pharmaceuticals Inc.TerminatedHepatitis C InfectionUnited States